Genetic polymorphisms of cyclooxygenase-2 and colorectal adenoma risk: The Self Defense Forces Health Study

Cancer Science

Volumn 99, Issue 3, 2008, Pages 576-581

  Ueda, Naoyuki ^a   Maehara, Yoshihiko ^a   Tajima, Osamu ^b   Tabata, Shinji ^c   Wakabayashi, Keiji ^d   Kono, Suminori ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Self Defense Forces Kumamoto Hospital   (Japan)

^c Self Defense Forces Fukuoka Hospital   (Japan)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GENOMIC DNA;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; COLONOSCOPY; COLORECTAL ADENOMA; CONTROLLED STUDY; DNA EXTRACTION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SOLDIER;

EID: 38949122308     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00711.x     Document Type: Article

References (30)

1. Dubois RN, Abramson SB, Crofford L et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-73.
2. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55: 115-22.
3. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: A new class of anticancer agents? Lancet Oncol 2003; 4: 605-15.
4. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404.
5. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-8.
6. Paganini-Hill A, Hsu G, Ross RK, Henderson BE. Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst 1991; 83: 1182-3.
7. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
8. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-6.
9. Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7.
10. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-9.
11. Sandler RS, Halabi S, Baron JA et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-90 [Erratum in N Engl J Med 2003; 348: 1939].
12. Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
13. Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-84.
14. Baron JA, Sandler RS, Bresalier RS et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-82.
15. Papafili A, Hill MR, Brull DJ et al. Common promoter variant in cyclooxygenase-2 represses gene expression: Evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 2002; 22: 1631-6.
16. Hamajima N, Takezaki T, Matsuo K et al. Genotype frequencies of cyclooxygenase 2 (COX2) rare polymorphisms for Japanese with and without colorectal cancer. Asian Pac J Cancer Prev 2001; 2: 57-62.
17. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC. Interaction between cyclooxygenase-2 gene polymorphism and dietary n-6 polyunsaturated fatty acids on colon cancer risk: The Singapore Chinese Health Study. Br J Cancer 2004; 90: 1760-4.
18. Cox DG, Pontes C, Guino E et al. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. Br J Cancer 2004; 91: 339-43.
19. Ulrich CM, Whitton J, YuJH et al. PTGS2 (COX-2)-765G>C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14: 616-19.
20. Zhang X, Miao X, Tan W et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-76.
21. Liu F, Pan K, Zhang X et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006; 130: 1975-84.
22. Toyomura K, Yamaguchi K, Kawamoto H et al. Relation of cigarette smoking and alcohol use to colorectal adenomas by subsite: The Self-Defense Forces Health Study. Cancer Sci 2004; 95: 72-6.
23. Hirose M, Kono S, Tabata S et al. Genetic polymorphisms of methylenetetrahydrofolate reductase and aldehyde dehydrogenase 2, alcohol use and risk of colorectal adenomas: Self-Defense Forces Health Study. Cancer Sci 2005; 96: 513-18.
24. Tabata S, Yin G, Ogawa S, Yamaguchi K, Mineshita M, Kono S. Genetic polymorphism of cholesterol 7á-hydroxylase (CYP7A1) and colorectal adenomas: The Self Defense Forces Health Study. Cancer Sci 2006; 97: 406-10.
25. Cipollone F, Toniato E, Martinotti S et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 2004; 291: 2221-8.
26. Orbe J, Beloqui O, Rodriguez JA, Belzunce MS, Roncal C, Paramo JA. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors. Clin Chim Acta 2006; 368: 138-43.
27. Abdullah L, Ait-Chezala G, Crawford F et al. The cyclooxygenase 2-765C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett 2006; 395: 240-3.
28. Pereira C, Sousa H, Ferreira P et al. -765G>C COX-2 polymorphism may be a susceptibility marker for gastric adenocarcinoma in patients with atrophy or intestinal metaplasia. World J Gastroenterol 2006; 12: 5473-8.
29. Lin HJ, Lakkides KM, Keku TO et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002; 11: 1305-15.
30. Sansbury LB, Millikan RC, Schroeder JC et al. COX-2 polymorphism, use of nonsteroidal anti-inflammatory drugs, and risk of colon cancer in African Americans (United States). Cancer Causes Control 2006; 17: 257-66.